ims health inc. Resources | BNET
On CNET: Apple taking steps against hackers

BNET Industries

IMS Health Inc. (RX) is in the Technology Industry

Revenue
Dec 31 2007
$2.1B
Profit
Dec 31 2007
$234.0M
Market Cap
Jul 07 2008
$4.1B

Latest News and Analysis

Additional Resources

  • Par Pharmaceutical Receives Final Approval to Market Generic Marinol® CIII Capsules

    Par to Begin Shipping Dronabinol Soft Gel Capsules Immediately WOODCLIFF LAKE, N.J., June 30 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for dronabinol, a generic version...

    Articles 2008-06-30

  • IMS Health Reports Global Biotech Sales Grew 12.5 Percent in 2007, Exceeding $75 Billion

    NORWALK, Conn. -- Global prescription sales of biotech drugs increased 12.5 percent in 2007 to more than $75 billion, according to a new report by IMS Health (NYSE: RX), the world's leading provider of market intelligence to the pharmaceutical and healthcare industries. The global biotech market grew at nearly double...

    Articles 2008-06-17

  • Lupin Receives USFDA Approval for Escitalopram Oxalate Tablets

    BALTIMORE, June 16 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. LPI announced today that it has received tentative approval for the Company's Abbreviated New Drug Application ANDA for Escitalopram Oxalate Tablets 10 mg and 20 mg from the U.S. Food and Drug Administration USFDA. Lupin's Escitalopram tablets are the...

    Articles 2008-06-16

  • Mylan Announces Tentative FDA Approval for Generic Version of Antihypertensive Avalide® Tablets

    PITTSBURGH, June 16 /PRNewswire-FirstCall/ -- Mylan Inc. today announced that its subsidiary, Mylan Pharmaceuticals Inc., has received tentative approval from the U.S. Food and Drug Administration FDA for its Abbreviated New Drug Application ANDA for Irbesartan and Hydrochlorothiazide Tablets, 150 mg/12.5 mg and 300 mg/12.5 mg. ...

    Articles 2008-06-16

  • Lupin Launches Ramipril Capsules

    BALTIMORE, June 11 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration FDA has granted final approval for the Company's Abbreviated New Drug Application ANDA for Ramipril capsules, 1.25 mg. 2.5 mg, 5 mg and 10 mg. Commercial shipments of the product have...

    Articles 2008-06-11

  • IMS to Present at William Blair Growth Stock Conference on June 17 at 1:40 p.m. CDT

    NORWALK, Conn. -- IMS Health (NYSE: RX), the world's leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced that David Carlucci, chairman and chief executive officer, will speak to investors and analysts attending the William Blair & Co. 28th Annual Growth Stock Conference, to be held...

    Articles 2008-06-10

  • Mylan Announces Final FDA Approval for Zaleplon Capsules

    PITTSBURGH, June 9 /PRNewswire-FirstCall/ -- Mylan Inc. today announced that its subsidiary, Genpharm ULC, has received final approval from the U.S. Food and Drug Administration FDA for its Abbreviated New Drug Application ANDA for Zaleplon Capsules, 5 mg and 10 mg. Zaleplon Capsules are the generic...

    Articles 2008-06-09

  • IMS to Present at Goldman Sachs Global Healthcare Conference on June 10 at 2:40 p.m. PT

    NORWALK, Conn. -- IMS Health (NYSE: RX), the world's leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced that David Carlucci, chairman and chief executive officer, will speak to investors and analysts attending the Goldman Sachs 29th Annual Global Healthcare Conference, to be held at The...

    Articles 2008-06-04

  • Lupin Receives USFDA Approval for Topiramate Tablets

    BALTIMORE, May 30 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. LPI announced today that it has received tentative approval for the Company's Abbreviated New Drug Application ANDA for Topiramate tablets, 25 mg, 50 mg, 100 mg and 200 mg from the U.S. Food and Drug Administration USFDA. Lupin's Topiramate...

    Articles 2008-05-30

Sort byClose

View Related Content by Tag Close

  • Incorporated: 1998
  • CEO: Mr. David R. Carlucci

IMS Health is a global provider of market intelligence to the pharmaceutical and healthcare industries. Co. provides products and services for its clients' day-to-day operations, including portfolio optimization capabilities; launch and brand management services; sales force effectiveness; managed markets and consumer health offerings; and consulting and services offerings that are intended to improve the delivery of healthcare worldwide. Co.'s information products are developed to meet client needs by using data secured from a worldwide network of suppliers in more than 100 countries.

Key Competitors

advertisement
IMS Health Inc. Company Info

Board of Directors

Mr. David R. Carlucci

Chairman

Mr. William C. Van Faasen

Lead Director

Mr. Constantine L. Clemente

Ms. Kathryn E. Giusti

Mr. M. Bernard Puckett

Mr. John P. Imlay Jr.

Mr. H. Eugene Lockhart

Mr. James D. Edwards

Mr. Bret W. Wise

Contact Information

1499 Post Road

Fairfield, CT

http://www.imshealth.com

203 845-5200

NAICS Code

Data Processing, Hosting, and Related Services: 518210
Brought to you by IBMSponsored Resources
advertisement